Clinical Trials Logo

Pyoderma clinical trials

View clinical trials related to Pyoderma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05561816 Completed - Pyoderma Clinical Trials

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Start date: July 19, 2022
Phase: Phase 3
Study type: Interventional

The study is aimed to: - evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma, - evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.

NCT ID: NCT04895566 Completed - Clinical trials for Pyoderma Gangrenosum

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

Start date: May 24, 2021
Phase: Early Phase 1
Study type: Interventional

Phase 0/1 local application of the monoclonal antibody (Mab) sB24M in patients with purulent pyoderma (chronic ulcerative pyoderma) by injection into the affected areas. Monoclonal antibody (Mab) sB24 negatively regulates immune-inflammatory processes through CD47 / TNF-α Axis promotes epithelialization of damaged tissue.

NCT ID: NCT03971643 Completed - Clinical trials for Pyoderma Gangrenosum

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Start date: May 16, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.

NCT ID: NCT03311464 Completed - Clinical trials for Pyoderma Gangrenosum

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Start date: October 27, 2017
Phase: Phase 3
Study type: Interventional

This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).

NCT ID: NCT03137160 Completed - Clinical trials for Pyoderma Gangrenosum

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Start date: May 4, 2017
Phase: Phase 2
Study type: Interventional

An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

NCT ID: NCT02733094 Completed - Clinical trials for Pyoderma Gangrenosum

Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

Start date: April 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of anti-Interleukin-(IL)17 therapy (secukinumab, administered weekly for 4 weeks followed by four-weekly administration until week 16) for the treatment of pyoderma gangrenosum.

NCT ID: NCT01965613 Completed - Clinical trials for Pyoderma Gangrenosum

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Start date: January 31, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

NCT ID: NCT01882504 Completed - Clinical trials for Pyoderma Gangrenosum

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.

NCT ID: NCT01302795 Completed - Clinical trials for Pyoderma Gangrenosum

Canakinumab for Pyoderma Gangrenosum

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.

NCT ID: NCT00884728 Completed - Scabies Clinical Trials

Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory

EAHSP
Start date: September 2004
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether a coordinated regional approach to healthy skin programs in six remote Aboriginal communities can demonstrate, not only a reduction in the burden of scabies and streptococcal skin sores, but also broad health benefits, including primary prevention of some chronic diseases that occur at particularly high rates in Australian Aboriginal communities. The primary objectives of the Program are: - Demonstrate a reduction in scabies and skin sores on a regional basis - Demonstrate the broader public health effects of Healthy Skin Programs, particularly those relating to chronic diseases such as rheumatic fever and renal diseases - Build on the existing Indigenous capacity by assisting in the development of new knowledge and skills to improve the health and well being of Indigenous communities - Establish the feasibility of incorporating Healthy Skin Programs into existing health service delivery